TY - JOUR
T1 - Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma
T2 - Clinical and molecular analyses of a phase 3 study
AU - Tacchetti, Paola
AU - Terragna, Carolina
AU - Galli, Monica
AU - Zamagni, Elena
AU - Petrucci, Maria Teresa
AU - Pezzi, Annalisa
AU - Montefusco, Vittorio
AU - Martello, Marina
AU - Tosi, Patrizia
AU - Baldini, Luca
AU - Peccatori, Jacopo
AU - Ruggieri, Miriana
AU - Pantani, Lucia
AU - Lazzaro, Antonio
AU - Elice, Francesca
AU - Rocchi, Serena
AU - Gozzetti, Alessandro
AU - Cavaletti, Guido
AU - Palumbo, Antonio
AU - Cavo, Michele
PY - 2014/12/1
Y1 - 2014/12/1
N2 - A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation (ASCT) for multiple myeloma (MM). A total of 236 patients randomized to VTD and 238 to TD were stratified according to the emergence of grade ≥2 PN. Gene expression profiles (GEP) of CD138+ plasma cells were analyzed in 120 VTD-treated patients. The incidence of grade ≥2 PN was 35% in the VTD arm and 10% in the TD arm (P
AB - A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation (ASCT) for multiple myeloma (MM). A total of 236 patients randomized to VTD and 238 to TD were stratified according to the emergence of grade ≥2 PN. Gene expression profiles (GEP) of CD138+ plasma cells were analyzed in 120 VTD-treated patients. The incidence of grade ≥2 PN was 35% in the VTD arm and 10% in the TD arm (P
UR - http://www.scopus.com/inward/record.url?scp=84908445489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908445489&partnerID=8YFLogxK
U2 - 10.1002/ajh.23835
DO - 10.1002/ajh.23835
M3 - Article
C2 - 25159313
AN - SCOPUS:84908445489
VL - 89
SP - 1085
EP - 1091
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 12
ER -